Assignee
ACERTA PHARMA BV
NL·21 granted patents·35 pending applications·67 citations·filing 2013–2025
Top patents by PatentIndex Score
56 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0593US9796721B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2016·Granted Oct 24, 2017·12 cites·17 claims
- 0691US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0788US9522917B2Bruton's tyrosine kinase inhibitors for hematopoietic mobilizationACERTA PHARMA BV·Filed 2013·Granted Dec 20, 2016·6 cites·22 claims
- 0886US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0984US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 1084US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1182US2025090525A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 1282US2024199622A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1380US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1478US11820777B2Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2022·Granted Nov 21, 2023·0 cites·27 claims
- 1578US10167291B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2017·Granted Jan 1, 2019·1 cites·28 claims
- 1677US11110088B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2020·Granted Sep 7, 2021·1 cites·2 claims
- 1773US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1872US12448387B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2024·Granted Oct 21, 2025·0 cites·31 claims
- 1971US11059829B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleateACERTA PHARMA BV·Filed 2020·Granted Jul 13, 2021·0 cites·42 claims
- 2071US10640509B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphomaACERTA PHARMA BV·Filed 2018·Granted May 5, 2020·0 cites·20 claims
- 2171US2022177476A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2270US12024520B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2019·Granted Jul 2, 2024·1 cites·29 claims
- 2370US2024335431A11-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDSACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 2469US2021322408A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2569US2019314369A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2668US11154554B2Therapeutic combinations of a MEK inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Oct 26, 2021·0 cites·4 claims
- 2768US10736893B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2016·Granted Aug 11, 2020·1 cites·2 claims
- 2867US2024197742A1Therapeutic Combinations of a CD19 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 2966US2019231775A1Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3064US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3163US2018193337A1Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3262US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3361US2019209591A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3460US9937171B2Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2015·Granted Apr 10, 2018·0 cites·17 claims
- 3559US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3658US2018318304A1Methods of Using BTK Inhibitors to Treat DermatosesACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3758US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3857US2020069668A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3956US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4056US2025360112A11-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDSACERTA PHARMA BV·Filed 2025·Application pending·0 cites
- 4156US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 4255US2017035881A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4355US2019008869A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4454US2017224688A1Methods of Using BTK Inhibitors to Treat DermatosesACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4554US2017143712A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4654US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4754US2017071962A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4854US2019008859A1Therapeutic Combinations of a MEK Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4953US2019374543A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 5052US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ACERTA PHARMA BV files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →